Business
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of
About this update from Exagen Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Selected as a Featured Poster and ACR’s Ignite Talk is “Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy,” part of the core technology powering Exagen’s AVISE® RADR test development. In addition, data from Exagen’s research on machine learning in patients with fibromyalgia has been accepted for an oral presentation. Exagen’s President and Chief Executive Officer, Ron Rocca, shared, “Exagen is honored to have nine scientific abstracts accepted for ACR’s 2022 annual conference, with a featured poster focusing on AVISE® RADR and a podium presentation. We continue to assist physicians by adding clarity to their clinical diagnoses by providing precision testing; we believe good science leads to good decisions.” Below is the list of accepted abstracts, with links to each: Saturday, November 12, 2022 Poster Presentation | Presented by Geoffrey Stephens, PhD | Abstract #0324 Title: Comparison of nCounter® and BioFire® Technologies for the Measurement of Type I Interferon SignatureSession Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis Session Time: 1:00 – 3:00pm ET Sunday, November 13, 2022 Featured Poster Presentation | Presented by Giorgio Casaburi, PhD | Abstract #0935 Title: Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological TherapySession Title: RA – Treatment Poster II Session Time: 9:00 – 10:30am ET Poster Presentation | Presented by Anca Askanase, MD | Abstract #1442 Title: Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythemato...